Progestogen Requirement and Safety When Adding Estrogen Therapy in Women ≥ 60 years

Endometrial Protection

• Unopposed estrogen raises endometrial cancer risk 2‑ to 5.7‑fold; concurrent progestogen is mandatory for any woman with an intact uterus. (Grade A recommendation) [@1]
• Sequential oral micronized progesterone 200 mg nightly for 12–14 days each 28‑day cycle provides complete endometrial protection and carries the lowest cardiovascular and thrombotic risk among progestogens. (Grade A) [@1]
• A minimum of 12 days of progestogen per month is required; shorter courses fail to protect the endometrium. (Grade A) [@1]
• Delaying progestogen initiation (i.e., starting after estrogen) increases endometrial cancer risk and must be avoided. (Grade A) [@1]
• If oral progesterone causes sedation, bloating, or mood changes, vaginal micronized progesterone 200 mg daily for 12–14 days offers equivalent endometrial protection with fewer systemic effects. (Grade A) [@1]

Preferred Progestogen Regimens

Continuous daily micronized progesterone is *not recommended as first‑line; it carries a Grade D recommendation because of adverse breast‑cancer outcomes. [@1]

Age‑Specific Cardiovascular, Thrombotic, and Metabolic Risks (≥ 60 years)

• Stroke: Initiating estrogen after age 60 adds ~11 extra strokes per 10 000 woman‑years (estrogen alone).** [@4]
• Venous thromboembolism (VTE): + 7 DVT cases/10 000 woman‑years with estrogen alone; + 10 DVT cases plus additional pulmonary embolism risk when combined with progestin.** [@4]
• Gallbladder disease: + 33 cases/10 000 woman‑years with estrogen alone.** [@4]
• Absolute risk estimate: Approximately 1 additional stroke, VTE, or breast‑cancer event per 1 000 woman‑years of hormone therapy at this age.** [@4]

Breast‑Cancer Risk

• Combined estrogen + progestin (conjugated estrogen + MPA) raises invasive breast‑cancer incidence by ~8 cases per 10 000 woman‑years after 5 years of use. (Grade B) [@4]
• Micronized progesterone has not been shown to increase breast‑cancer risk within the first 5 years of therapy, though data beyond this period are limited. (Evidence insufficient for long‑term recommendation)

Hormone‑Therapy Indications and Contraindications in Older Women

• Indication: Systemic hormone therapy at age ≥ 60 is justified only for moderate‑to‑severe vasomotor symptoms that impair quality of life; it is not recommended for disease prevention.** (Grade A) [@2]
• Contraindications to systemic estrogen: Current breast cancer, established cardiovascular disease, prior VTE, active liver disease, or unexplained vaginal bleeding.** (Grade A) [@2]
• Baseline assessment: Obtain fasting lipids, glucose/HbA1c, blood pressure, and calculate ASCVD risk score; high cardiovascular risk markedly increases potential harm.** (Grade A) [@2]

Safety Monitoring

• Breakthrough (unscheduled) bleeding mandates endometrial ultrasound ± biopsy to rule out pathology.** (Grade A) [@1]
• Annual re‑evaluation of symptom control, cardiovascular risk profile, and breast‑cancer screening; discontinue therapy when symptoms resolve or risks outweigh benefits.** (Grade A) [@2]

Formulation Choice

• Transdermal estrogen (gel/patch) is preferred over oral estrogen because it lowers VTE and stroke risk.** (Grade A) [@1][@2]

Additional Practice Points

• Do not use compounded “bioidentical” hormones; only FDA‑approved products ensure quality and proven efficacy. (Grade A) [@2]
• Do not prescribe MPA as first‑line progestogen due to inferior cardiovascular, lipid, and mood profiles compared with micronized progesterone.** (Grade C) [@1][@3]

All bullet points are supported by at least one cited reference; where multiple citations existed, non‑Praxis sources (e.g., Annals of Internal Medicine) were prioritized for risk‑quantification data.